Inhibition of mtor in kidney cancer

Current Oncology

Volumn 16, Issue S1, 2009, Pages S33-S39

  Kapoor, Anil ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

everolimus; kidney cancer; mtor inhibitors; renal cell carcinoma; sirolimus; Temsirolimus

Indexed keywords

EID: 76049084645     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v16i0.419     Document Type: Article

References (31)

1. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115–24.
2. Escudier B, Eisen T, Stadler WM, et al. on behalf of the target Study Group. Sorafenib in advanced clear-cell renal-cell car-cinoma. N Engl J Med 2007;356:125–34. [Erratum in: N Engl J Med 2007;357:203]
3. Hudes G, Carducci M, Tomczak P, et al. on behalf of the Global arcc Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271–81.
4. Bjornsti MA, Houghton PJ. The tor pathway: a target for cancer therapy. Nat Rev Cancer 2004;4:335–48.
5. Adjei AA, Hidalgo M. Intracellular signal transduction pathway proteins as targets for cancer therapy. J Clin Oncol 2005;23:5386–403.
6. Jacinto E, Loewith R, Schmidt A, et al. Mammalian t o r complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004;6:1122–8.
7. Hresko RC, Mueckler M. mtor.rictor is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem 2005;280:40406–16.
8. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphoryl-ation and regulation of Akt/pkb by the rictor-mtor complex. Science 2005;307:1098–101.
9. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943–7.
10. Sansal I, Sellers WR. The biology and clinical relevance of the pten tumor suppressor pathway. J Clin Oncol 2004;22:2954–63.
11. Houghton PJ, Huang S. mtor as a target for cancer therapy. Curr Top Microbiol Immunol 2004;279:339–59.
12. Eng CP, Sehgal SN, Vézina C. Activity of rapamycin (AY-22,989) against transplanted tumors. J Antibiot (Tokyo) 1984;37:1231–7.
13. Sehgal SN. Rapamune (rapa, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998;31:335–40.
14. Luan FL, Hojo M, Maluccio M, Yamaji K, Suthanthiran M. Rapamycin blocks tumor progression: unlinking immuno-suppression from antitumor efficacy. Transplantation 2002;73:1565–72.
15. Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 1994;372:570–3.
16. Luan FL, Ding R, Sharma VK, Chon WJ, Lagman M, Suth-anthiran M. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 2003;63:917–26.
17. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogen-esis: involvement of vascular endothelial growth factor. Nat Med 2002;8:128–35. [See comment]
18. Amato RJ, Jac J. Targeted anti-cancer therapies for renal cancer. Drugs 2006;66:2161–71.
19. Motzer RJ, Escudier B, Oudard S, et al. on behalf of the rec-ord-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase iii trial. Lancet 2008;372:449–56.
20. Yu K, Toral–Barza L, Discafani C, et al. mtor, a novel target in breast cancer: the effect of CCI-779, an mto r inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001;8:249–58.
21. Raymond E, Alexandre J, Faivre S, et al. Safety and pharma-cokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mtor inhibitor, in patients with cancer. J Clin Oncol 2004;22:2336–47.
22. Schmelzle T, Hall MN. tor, a central controller of cell growth. Cell 2000;103:253–62.
23. Skotnicki JS, Leone CL, Smith AL, et al. Design, synthesis and biological evaluation of C-42 hydroxyesters of rapamycin: the identification of CCI-779 [abstract 477]. Clin Cancer Res 2001;7(suppl):3749S–50S.
24. Thomas GV, Tran C, Mellinghoff IK, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mtor in kidney cancer. Nat Med 2006;12:122–7.
25. Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 2000;19:6680–6.)
26. Forouzesh B, Buckner J, Adjei A, et al. Phase 1, bioavailabil-ity, and pharmacokinetic study of the oral dosage of CCI-779 administered to patients with advanced solid malignancies [abstract 168]. Eur J Cancer 2002;38(suppl 7):54.
27. Punt CJ, Boni J, Bruntsch U, Peters M, Thielert C. Phase i and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Ann Oncol 2003;14:931–7.
28. Chang SM, Kuhn J, Wen P, et al. on behalf of the North Ameri-can Brain Tumor Consortium and the National Cancer Institute. Phase i/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest New Drugs 2004;22:427–35.
29. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase ii study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22:909–18.
30. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289–96.
31. Smith JW, Ko YJ, Dutcher J, et al. Update of a phase 1 study of intravenous CCI-779 given in combination with interferon-α to patients with advanced renal cell carcinoma. Proc Am Soc Clin Oncol 2004;22:. [Available online at: www.asco.org/asco/ Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_ detail_view&confID=26&abstractID=433; cited March 22, 2009]